friday june 3 1994 part viii depart health human servic food drug administr 21 cfr part 341 cold cough allergi bronchodil antiasthmat drug product counter human use final rule feder regist vol 59 106 friday june 3 1994 rule regul usdept depart health human servic usdept usbureau food drug administr usbureau 21 cfr part 341 rindock docket 89p0040 rindock rindock rin 0905aa06 rindock cold cough allergi bronchodil antiasthmat drug product counter human use amend final monograph otc antituss drug product agenc agenc food drug administr hh agenc action action final rule action summari summari food drug administr fda issu final rule amend final monograph counter otc antituss drug product includ ingredi diphenhydramin citrat diphenhydramin hydrochlorid otc antituss drug product use reliev cough final rule address singl ingredi antituss drug product contain one ingredi futur issu feder regist agenc propos amend tent final monograph otc cold cough allergi bronchodil antiasthmat combin drug product address combin cough cold drug product contain diphenhydramin citrat diphenhydramin hydrochlorid final rule part ongo review otc drug product conduct fda summari date effect date june 5 1995 date inform contact william e gilbertson center drug evalu research hfd810 food drug administr 5600 fisher lane rockvil md 20857 3015945000 supplem supplementari inform background feder regist august 12 1987 52 fr 30042 fda issu final monograph otc antituss drug product part 341 21 cfr part 341 list 341 14 21 cfr 341 14 activ ingredi gener recogn safe effect use product diphenhydramin citrat diphenhydramin hydrochlorid includ 341 14 time subsequ two manufactur petit agenc amend final monograph otc antituss drug product includ diphenhydramin citrat diphenhydramin hydrochlorid monograph activ ingredi ref 1 2 petit display docket manag branch hfa305 food drug administr rm 123 12420 parklawn dr rockvil md 20857 feder regist decemb 9 1992 57 fr 58378 agenc discuss petit propos diphenhydramin citrat diphenhydramin hydrochlorid gener recogn safe effect otc antituss use agenc previous determin diphenhydramin citrat bioequival therapeut equival diphenhydramin hydrochlorid 54 fr 6814 6824 februari 14 1989 agenc propos specif warn direct ingredi otc antituss use agenc advis propos rule 57 fr 58378 58380 final rule result propos rule would effect 12 month final rule date public feder regist agenc invit written comment februari 8 1993 propos rule agenc econom impact determin propos respons propos rule agenc receiv two comment manufactur copi comment public display docket manag branch address refer 1 comment cp2 docket 89p0040 docket manag branch 2 comment cp3 docket 89p0040 docket manag branch ii agenc conclus comment 1 two comment request agenc propos otc antituss dosag diphenhydramin hydrochlorid 25 milligram mg everi 4 hour h exceed 150 mg 24 h expand rang 25 50 mg everi 4 6 h exceed 300 mg 24 h one comment also request correspond expans otc antituss dosag diphenhydramin citrat e dosag 38 76 mg everi 4 6 h exceed 456 mg 24 h support expand dosag rang antituss use one comment provid pharmacokinet data diphenhydramin hydrochlorid dose 25 mg everi 4 h 50 mg everi 6 h data includ follow steadi state concentr c ss minimum concentr steadi state c ss min maximum concentr steadi state c ss max nanogram millilit ng ml dosag area curv auc dosag ng x h ml tabl 1diphenhydramin hydrochlorid pharmacokinet data 2 2 c ss max 2 c ss min 2 c ss 2 auc 25 mg everi 4 h i055 ng ml i027 5 ng ml i040 ng ml i0160 ng x h ml 50 mg everi 6 h i085 ng ml i030 ng ml i052 ng ml i0312 ng x h ml tabl comment point two c ss min concentr compar comment state 50 mg everi 6 h dose regimen efficaci 25 mg everi 4 h regimen 50 mg dose fall minimum effect concentr comment ad substanti provid c ss auc data fall within minimum effect concentr level comment state potenti conflict differ dosag antituss antihistamin use diphenhydramin would elimin accept broader antihistamin dosag e g diphenhydramin hydrochlorid 25 50 mg everi 4 6 h exceed 300 mg 24 h product intend use comment ad approach would reduc potenti consum confus comment argu would consum interest establish lower dose diphenhydramin product meet consum expect antihistamin effect comment contend base establish safeti diphenhydramin citrat diphenhydramin hydrochlorid antituss antihistamin use monograph statu four use potenti use one indic cough cold product broader dosag rang e g diphenhydramin hydrochlorid 25 50 mg everi 4 6 h permit provid maximum effect comment conclud diphenhydramin hydrochlorid found safe varieti otc use dosag 25 50 mg everi 4 6 h thu safeti issu dosag rang feder regist septemb 9 1976 41 fr 38312 38341 advisori review panel otc cold cough allergi bronchodil antiasthmat drug product base 25 mg everi 4 h recommend diphenhydramin hydrochlorid antituss use data demonstr effect accept toler dosag approv applic diphenhydramin hydrochlorid otc antituss dosag 25 mg everi 4 h base support clinic data clinic data receiv agenc support safeti increas effect higher dosag diphenhydramin hydrochlorid diphenhydramin citrat otc antituss use either otc drug review approv applic one comment submit pharmacokinet data concern diphenhydramin 25 mg everi 4 h dose 50 mg everi 6 h dose show c ss min regimen similar therefor like dose 50 mg everi 6 h effect regimen howev produc higher c ss max almost twice drug exposur increas potenti advers effect sedat evid greater effect everi 4 h regimen conclus agenc cannot consid gener recogn safe effect antituss dosag 25 50 mg everi 4 6 h diphenhydramin hydrochlorid support clinic data therefor base panel recommend dosag approv applic label otc antituss drug product contain diphenhydramin hydrochlorid agenc establish monograph antituss dosag diphenhydramin hydrochlorid follow adult children 12 year age oral dosag 25 milligram everi 4 hour exceed 150 milligram 24 hour direct doctor children 6 12 year age oral dosag 12 5 milligram everi 4 hour exceed 75 milligram 24 hour direct doctor children 6 year age consult doctor monograph antituss dosag diphenhydramin citrat follow adult children 12 year age oral dosag 38 milligram everi 4 hour exceed 228 milligram 24 hour direct doctor children 6 12 year age oral dosag 19 milligram everi 4 hour exceed 114 milligram 24 hour direct doctor children 6 year age consult doctor respect comment discuss singl ingredi drug product contain diphenhydramin concurr use antihistamin antituss issu address amend otc cough cold combin tent final monograph futur issu feder regist 2 one comment discuss multius label otc drug product contain diphenhydramin comment describ label product proven pharmacolog activ drug whether condit treat relat exampl comment state product contain diphenhydramin could label antituss antihistamin use occur statement ident could express cough suppress antihistamin comment state product label could describ use separ product indic accompani warn direct use comment contend legal restrict prevent multius label whether condit treat relat comment discuss sever aspect multius label final rule address singl ingredi diphenhydramin citrat diphenhydramin hydrochlorid drug product antituss use agenc acknowledg multius label possibl product contain diphenhydramin awar product current marketplac agenc intend address multius label futur issu feder regist amend tent final monograph otc cough cold combin drug product agenc discuss 1 concurr use diphenhydramin antituss antihistamin concurr symptom 2 differ use diphenhydramin separ full label differ nonconcurr symptom manufactur may introduc diphenhydramin product multius label otc marketplac agenc propos done appear futur issu feder regist 3 one comment contend agenc statement propos rule appear inconsist agenc gener provis administr procedur market otc combin drug product 21 cfr 330 13 b 2 complianc polici guid 7132b 16 agenc statement said agenc amend tent final monograph otc cough cold combin drug product cough cold combin drug product contain diphenhydramin citrat diphenhydramin hydrochlorid label antituss use market otc unless subject approv nda anda 57 fr 58378 58380 comment state fda recogn diphenhydramin otc antihistamin otc antituss market diphenhydramin claim combin drug product allow provis tent final monograph otc cough cold combin drug product comment list number exampl antituss combin antihistamin state diphenhydramin abl perform function product comment contend approach accept provid label use categori combin final rule address combin drug product contain diphenhydramin citrat diphenhydramin hydrochlorid antituss activ ingredi number issu need resolv diphenhydramin use perform function antituss antihistamin singl product includ among other differ monograph direct use amount drug taken time interv take drug differ warn relat individu use agenc intend discuss matter futur issu feder regist note time agenc reaffirm posit state otc cough cold combin drug product contain diphenhydramin citrat diphenhydramin hydrochlorid label antituss use market subject approv applic comment receiv respons agenc request specif comment econom impact rulemak fda examin impact final rule execut order 12866 regulatori flexibl act pub l 96354 execut order 12866 direct agenc assess cost benefit avail regulatori altern regul necessari select regulatori approach maxim net benefit includ potenti econom environment public health safeti advantag distribut impact equiti agenc believ final rule consist regulatori philosophi principl identifi execut order addit final rule signific regulatori action defin execut order thu subject review execut order regulatori flexibl act requir agenc analyz regulatori option would minim signific impact rule small entiti current market otc singl ingredi diphenhydramin drug product alreadi meet condit final monograph manufactur abl enter otc marketplac without obtain approv applic accordingli agenc certifi final rule signific econom impact substanti number small entiti therefor regulatori flexibl act analysi requir agenc determin 21 cfr 25 24 c 6 action type individu cumul signific effect human environ therefor neither environment assess environment impact statement requir list subject 21 cfr part 341 label counter drug therefor feder food drug cosmet act author deleg commission food drug 21 cfr part 341 amend follow part 341_cold cough allergi bronchodil antiasthmat drug product counter human use 1 author citat 21 cfr part 341 continu read follow author sec 201 501 502 503 505 510 701 feder food drug cosmet act 21 u c 321 351 352 353 355 360 371 2 section 341 14 amend ad new paragraph 5 6 read follow 341 14 antituss activ ingredi 5 diphenhydramin citrat 6 diphenhydramin hydrochlorid 3 section 341 74 amend ad new paragraph c 4 vii c 4 viii c 4 ix 1 iv 1 v read follow 341 74 label antituss drug product c 4 vii product contain diphenhydramin citrat diphenhydramin hydrochlorid identifi 341 14 5 6 may caus excit especi children viii product contain diphenhydramin citrat diphenhydramin hydrochlorid identifi 341 14 5 6 label children 12 year age _ give product children breath problem chronic bronchiti glaucoma without first consult child doctor b may caus mark drowsi sed tranquil may increas drowsi effect give product children take sed tranquil without first consult child doctor ix product contain diphenhydramin citrat diphenhydramin hydrochlorid identifi 341 14 5 6 label use adult children 12 year age_ take product unless direct doctor breath problem emphysema chronic bronchiti glaucoma difficulti urin due enlarg prostat gland b may caus mark drowsi alcohol sed tranquil may increas drowsi effect avoid alcohol beverag take product take product take sed tranquil without first consult doctor use caution drive motor vehicl oper machineri 1 iv product contain diphenhydramin citrat identifi 341 14 5 adult children 12 year age oral dosag 38 milligram everi 4 hour exceed 228 milligram 24 hour direct doctor children 6 12 year age oral dosag 19 milligram everi 4 hour exceed 114 milligram 24 hour direct doctor children 6 year age consult doctor v product contain diphenhydramin hydrochlorid identifi 341 14 6 adult children 12 year age oral dosag 25 milligram everi 4 hour exceed 150 milligram 24 hour direct doctor children 6 12 year age oral dosag 12 5 milligram everi 4 hour exceed 75 milligram 24 hour direct doctor children 6 year age consult doctor 4 section 341 90 amend ad new paragraph r read follow 341 90 profession label r product contain diphenhydramin citrat identifi 341 14 5 children 2 6 year age oral dosag 9 5 milligram everi 4 hour exceed 57 milligram 24 hour product contain diphenhydramin hydrochlorid identifi 341 14 6 children 2 6 year age oral dosag 6 25 milligram everi 4 hour exceed 37 5 milligram 24 hour date may 16 1994 supplem signer michael r taylor signer signjob deputi commission polici signjob frfile fr doc 9413586 file 6294 8 45 frfile bill bill code 416001f bill